Chemically modified symmetric and asymmetric duplex RNAs: an enhanced stability to nuclease degradation and gene silencing effect.

The present study accents on the relationship between dicing, nuclease stability, and RNAi activity of various types of chemically modified symmetric and asymmetric dsRNAs, covalently bound with amino-groups or cholesterol at one or both terminals. All modified dsRNAs were subjected to cleavage by recombinant Dicer enzyme. They possessed a high resistance to nuclease degradation in cell cultured medium and an excellent RNAi activity in viable cells. The best stability and RNAi activity was detected for 5'-sense amino-modified RNAs. These modifications manifested also a high long-term gene silencing effect within seven days post-transfection, while the RNAi activity of the native 21nt siRNA expired within two days. The conjugation of dsRNA with cholesterol at 5'-sense end resulted in easy intracellular delivery without transfection reagents. After a direct transfection in cells, the cholesterol-conjugated 27nt dsRNA possessed a higher RNAi activity than cholesterol-conjugated 21nt siRNA.

[1]  Joshua T. Jones,et al.  Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing , 2003, Nature Biotechnology.

[2]  B. Sullenger,et al.  Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. , 2007, Oligonucleotides.

[3]  C. Hornyik,et al.  A viral protein suppresses RNA silencing and binds silencing‐generated, 21‐ to 25‐nucleotide double‐stranded RNAs , 2002, The EMBO journal.

[4]  P. Whittaker,et al.  RNA interference: From gene silencing to gene-specific therapeutics , 2005, Pharmacology & Therapeutics.

[5]  H. Ohba,et al.  Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity. , 2007, Oligonucleotides.

[6]  K. Morris,et al.  Lentiviral-mediated delivery of siRNAs for antiviral therapy , 2006, Gene Therapy.

[7]  K. Alexander,et al.  High potency silencing by single-stranded boranophosphate siRNA , 2006, Nucleic acids research.

[8]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[9]  Sangdun Choi,et al.  Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy , 2005, Nature Biotechnology.

[10]  T. Rana,et al.  Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. , 2004, Chemistry & biology.

[11]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[12]  Paul A. Serbinowski,et al.  A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells , 2006, Nature Biotechnology.

[13]  Simon W. Jones,et al.  MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. , 2007, Molecular bioSystems.

[14]  Hideyoshi Harashima,et al.  RNA interference induced by siRNAs modified with 4′‐thioribonucleosides in cultured mammalian cells , 2005, FEBS letters.

[15]  B. Baker,et al.  Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. , 2006, RNA.

[16]  T. Rana,et al.  siRNA function in RNAi: a chemical modification analysis. , 2003, RNA.

[17]  Z. Paroo,et al.  Biodistribution of phosphodiester and phosphorothioate siRNA. , 2004, Bioorganic & medicinal chemistry letters.

[18]  M. Manoharan.  RNA interference and chemically modified small interfering RNAs. , 2004, Current opinion in chemical biology.

[19]  Angela N. Brooks,et al.  Structural Basis for Double-Stranded RNA Processing by Dicer , 2006, Science.

[20]  David R Corey,et al.  RNA interference in mammalian cells by chemically-modified RNA. , 2003, Biochemistry.

[21]  Kazunori Kataoka,et al.  Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. , 2005, Journal of the American Chemical Society.

[22]  Anastasia Khvorova,et al.  Induction of the interferon response by siRNA is cell type- and duplex length-dependent. , 2006, RNA.

[23]  T. Tuschl,et al.  Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate , 2001, The EMBO journal.

[24]  Y. Baba,et al.  Antisense inhibition of Bcr‐Abl/c‐Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells1 , 2004, FEBS letters.

[25]  K. Taira,et al.  Functional gene-discovery systems based on libraries of hammerhead and hairpin ribozymes and short hairpin RNAs. , 2005, Molecular bioSystems.

[26]  Mark E. Davis,et al.  Functional polarity is introduced by Dicer processing of short substrate RNAs , 2005, Nucleic acids research.

[27]  K. Ui-Tei,et al.  Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. , 2004, Nucleic acids research.

[28]  A. Butte,et al.  Creation and implications of a phenome-genome network , 2006, Nature Biotechnology.

[29]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[30]  J. Couzin.  Small RNAs Make Big Splash , 2002, Science.

[31]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[32]  Y. Yuzawa,et al.  A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics , 2004, Cancer Research.

[33]  M. Eccles,et al.  Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells , 2004, FEBS letters.

[34]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[35]  T. Park,et al.  Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. , 2007, Biochemical and biophysical research communications.

[36]  J. Walder,et al.  Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma. , 1991, Antisense research and development.

[37]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[38]  Henning Urlaub,et al.  Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi , 2002, Cell.

[39]  Matthias John,et al.  Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. , 2004, Bioorganic & medicinal chemistry letters.

[40]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[41]  Simon W. Jones,et al.  RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. , 2007, Blood cells, molecules & diseases.